{"id":365090,"date":"2025-05-08T00:00:00","date_gmt":"2025-05-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0039-biopharma-diabetic-nephropathy-epidemiology-emerging-markets\/"},"modified":"2026-03-31T10:26:24","modified_gmt":"2026-03-31T10:26:24","slug":"epidmd0039-biopharma-diabetic-nephropathy-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0039-biopharma-diabetic-nephropathy-epidemiology-emerging-markets\/","title":{"rendered":"Diabetic Nephropathy &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of diabetic nephropathy (<abbr data-abbreviation-entity=\"6300\" title=\"diabetic nephropathy\">DN<\/abbr>) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the diagnosed prevalence of the disease for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>The patient populations are forecast over a period of 10 years for the countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr data-abbreviation-entity=\"6300\" title=\"diabetic nephropathy\">DN<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr data-abbreviation-entity=\"6300\" title=\"diabetic nephropathy\">DN<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts <abbr data-abbreviation-entity=\"6300\" title=\"diabetic nephropathy\">DN<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-365090","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-nephropathy","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/365090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/365090\/revisions"}],"predecessor-version":[{"id":464533,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/365090\/revisions\/464533"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=365090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}